Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2C
The experimentally established mechanism targets of Oxymetazoline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 6/20 | 0.97 |
| ▸ | ADRA2B known ✓ | P18089 | 5/20 | 0.97 |
| ▸ | ADRA2C known ✓ | P18825 | 5/20 | 0.97 |
| ▸ | ADRA1D known ✓ | P25100 | 5/20 | 0.97 |
| ▸ | ADRA1A known ✓ | P35348 | 5/20 | 0.97 |
| ▸ | ADRA1B known ✓ | P35368 | 5/20 | 0.97 |
| ▸ | HTR1D | P28221 | 11/20 | 0.97 |
| ▸ | HTR1B | P28222 | 11/20 | 0.97 |
| ▸ | HTR1A | P08908 | 4/20 | 0.97 |
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.97 |
| ▸ | TSHR | P16473 | 3/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.97 |
| ▸ | HTR2A | P28223 | 2/20 | 0.97 |
| ▸ | HTR2C | P28335 | 2/20 | 0.97 |
| ▸ | DRD3 | P35462 | 2/20 | 0.97 |
| ▸ | HTR2B | P41595 | 2/20 | 0.97 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxymetazoline SCHEMBL29825106 | 0.99 | HTR1D (1.00) | HTR1DHTR1BADRA2AADRA2BADRA2C | |
| Oxymetazoline SCHEMBL24301 | 0.99 | HTR1D (1.00) | HTR1DHTR1BADRA2AADRA2BADRA2C | |
| Oxymetazoline SCHEMBL30495496 | 0.97 | ADRA2A (1.00) | HTR1DHTR1BADRA2AADRA2BADRA2C | |
| Oxymetazoline SCHEMBL41247 | 0.97 | ADRA2A (1.00) | HTR1DHTR1BADRA2AADRA2BADRA2C | |
| Oxymetazoline SCHEMBL16115411 | 0.97 | HTR1D (0.97) | HTR1DHTR1BADRA2AADRA2BADRA2C | |
| Oxymetazoline SCHEMBL16115214 | 0.97 | HTR1D (0.97) | HTR1DHTR1BADRA2AADRA2BADRA2C | |
| Oxymetazoline SCHEMBL16114512 | 0.97 | HTR1D (0.97) | HTR1DHTR1BADRA2AADRA2BADRA2C | |
| Oxymetazoline SCHEMBL28206146 | 0.96 | ADRA2A (0.97) | HTR1DHTR1BADRA2AADRA2BADRA2C | |
| Oxymetazoline SCHEMBL8189197 | 0.94 | HTR1D (0.91) | HTR1DHTR1BADRA2AADRA2BADRA2C | |
| Oxymetazoline SCHEMBL4630526 | 0.94 | HTR1D (0.91) | HTR1DHTR1BADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101564396-A | Two chamber type nose spraying agent for treating allergic rhinitis | GUOPING YANG (CN) | 2009-10-28 | — | — | CN | claimed |
| CN-122075403-A | Oxymetazoline hydrochloride eye drop composition and preparation method thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-20230255940-A1 | OXYMETAZOLINE FOR THE TREATMENT OF ANO-RECTAL DISORDERS | RDD PHARMA LTD (IL) | 2023-08-17 | — | — | US | disclosed |
| US-20210046051-A1 | OXYMETAZOLINE FOR THE TREATMENT OF ANO-RECTAL DISORDERS | RDD PHARMA LTD. (IL) | 2021-02-18 | — | — | US | disclosed |
| US-20190175559-A1 | OXYMETAZOLINE FOR THE TREATMENT OF ANO-RECTAL DISORDERS | RDD PHARMA LTD. (IL) | 2019-06-13 | — | — | US | disclosed |
| CN-108368119-B | Fused Bicyclic Compounds for Inhibiting Tyrosine Kinase Activity | 深圳市塔吉瑞生物医药有限公司 | 2019-04-23 | — | — | CN | disclosed |
| US-20180207135-A1 | OXYMETAZOLINE FOR THE TREATMENT OF ANO-RECTAL DISORDERS | RDD PHARMA LTD. (IL) | 2018-07-26 | — | — | US | disclosed |
| CN-105517537-B | Composition for application to mucosa comprising cellulose ether | 陶氏环球技术有限责任公司 | 2018-04-17 | — | — | CN | disclosed |
| CN-107787322-A | Tricyclic compound and their purposes as phosphodiesterase inhibitors | 辉瑞大药厂 | 2018-03-09 | — | — | CN | disclosed |
| US-9849114-B2 | Oxymetazoline for the treatment of ano-rectal disorders | RDD PHARMA LTD. (IL) | 2017-12-26 | — | — | US | disclosed |
| CN-104546929-A | External medicine for resisting chronic peripheral inflammation and preparation method for external medicine | WUHAN BRIDGE BUILDER MEDICINE BIOTECHNOLOGY CO LTD | 2015-04-29 | — | — | CN | disclosed |
| EP-2701702-A2 | OXYMETAZOLINE FOR THE TREATMENT OF ANO-RECTAL DISORDERS | Rdd Pharma Ltd. (IL) | 2014-03-05 | — | — | EP | disclosed |
| US-20140051738-A1 | Oxymetazoline For The Treatment Of Ano-Rectal Disorders | RDD PHARMA LTD. (IL) | 2014-02-20 | — | — | US | disclosed |
| US-20130137099-A1 | TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN MAMMALIAN ORGANISMS | KYOTO UNIVERSITY (JP) | 2013-05-30 | — | — | US | disclosed |
| CN-102973574-A | Pharmaceutical composition for treating asthma and preparation method thereof | BEIJING YANFENGCHEN MEDICAL TECHNOLOGY DEV CO LTD | 2013-03-20 | — | — | CN | disclosed |
| WO-2012147084-A2 | OXYMETAZOLINE FOR THE TREATMENT OF ANO-RECTAL DISORDERS | RDD PHARMA LTD. (IL) | 2012-11-01 | — | — | WO | disclosed |
| EP-2234597-A1 | ENHANCING PHOTOSTABILIZATION OF OXYMETAZOLINE | Schering-Plough Healthcare Products, Inc. (US) | 2010-10-06 | — | — | EP | disclosed |
| US-20090281156-A1 | ENHANCING PHOTOSTABILIZATION OF OXYMETAZOLINE | SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC, | 2009-11-12 | — | — | US | disclosed |
| CN-101564396-A | Two chamber type nose spraying agent for treating allergic rhinitis | GUOPING YANG (CN) | 2009-10-28 | — | — | CN | disclosed |
| WO-2009086055-A1 | ENHANCING PHOTOSTABILIZATION OF OXYMETAZOLINE | SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281156-A1 | ENHANCING PHOTOSTABILIZATION OF OXYMETAZOLINE | EGLN3, PDE3A, QDPR | ADRA2A 127/4885ADRA2B 110/4885ADRA2C 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.